Giuseppe Schepisi
Overview
Explore the profile of Giuseppe Schepisi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
640
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Serra R, Giunta E, Schepisi G, Brighi N, Montanari D, Lolli C, et al.
Expert Rev Anticancer Ther
. 2024 Dec;
24(12):1221-1227.
PMID: 39716888
Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen...
2.
Giunta E, Caroli P, Scarpi E, Altavilla A, Rossetti V, Marini I, et al.
Eur J Nucl Med Mol Imaging
. 2024 Aug;
52(1):326-334.
PMID: 39207484
Purpose: to assess the utility of response monitoring to enzalutamide by using [Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy. Methods: patients underwent [Ga]Ga-PSMA PET less than...
3.
Casadei C, Scarpi E, Conteduca V, Gurioli G, Cursano M, Brighi N, et al.
Eur Urol Open Sci
. 2024 Feb;
61:44-51.
PMID: 38384439
Background: The prevalence of pathogenic germline mutations in DNA damage repair (gDDR) genes in the Italian population is unknown. Objective: In this prospective multicenter cohort study, we evaluated the prevalence...
4.
Conteduca V, Di Tullio P, Allamprese R, Bruno G, Lolli C, Schepisi G, et al.
Prostate Cancer Prostatic Dis
. 2024 Feb;
PMID: 38347113
Background: Currently, several therapies are available for metastatic castration-resistant prostate cancer (mCRPC) but no specific clinical factors to personalize treatment. We first sought the prognostic value of duration on androgen-deprivation...
5.
Urbini M, Bleve S, Schepisi G, Menna C, Gurioli G, Gianni C, et al.
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38069192
The outcome of metastatic testicular germ cell tumor patients has been dramatically improved by cisplatin-based chemotherapy combinations. However, up to 30% of patients with advanced disease relapse after first-line therapy...
6.
Farolfi A, Petracci E, Gurioli G, Tedaldi G, Casanova C, Arcangeli V, et al.
Front Oncol
. 2023 Sep;
13:1221096.
PMID: 37664032
Introduction: Primary debulking surgery (PDS), interval debulking surgery (IDS), and platinum-based chemotherapy are the current standard treatments for advanced ovarian cancer (OC). The time to initiation of adjuvant chemotherapy (TTC)...
7.
Conteduca V, Brighi N, Schepisi G, De Giorgi U
Br J Cancer
. 2023 Jul;
129(7):1050-1060.
PMID: 37443349
Prostate cancer is the most commonly diagnosed cancer but the management of advanced prostate cancer remains a therapeutic challenge, despite the survival benefits imparted by several therapeutic discoveries targeting different...
8.
Schepisi G, Gianni C, Palleschi M, Bleve S, Casadei C, Lolli C, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900394
Breast cancer represents one of the most common tumor histologies. To date, based on the specific histotype, different therapeutic strategies, including immunotherapies, capable of prolonging survival are used. More recently,...
9.
Schepisi G, Gianni C, Cursano M, Galla V, Menna C, Casadei C, et al.
Front Immunol
. 2023 Mar;
14:1118610.
PMID: 36860862
Germ cell tumors (GCTs) represent a heterogeneous neoplasm family affecting gonads and rarely occurring in extragonadal areas. Most of patients have a good prognosis, often even in the presence of...
10.
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
Gianni C, Palleschi M, Schepisi G, Casadei C, Bleve S, Merloni F, et al.
Front Oncol
. 2022 Aug;
12:882896.
PMID: 36003772
Adaptive and innate immune cells play a crucial role as regulators of cancer development. Inflammatory cells in blood flow seem to be involved in pro-tumor activities and contribute to breast...